Welcome to the Wyoming Chapter of the American College of Cardiology
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
For more information and to register, please visit: ACC Rockies Chapter Meeting 2026
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- The Evolut Low Risk Trial: Six-Year Outcomes of TAVR vs. SAVR in Patients at Low Surgical RiskThe Evolut Low Risk trial was a prospective randomized trial that enrolled patients at low surgical risk with severe trileaflet aortic stenosis from 87 international sites between 2016 and 2019.
- Eagle’s Eye View: Maintaining Weight Loss With TirzepatideIn this week’s View, Dr. Eagle examines recent research into maintaining weight loss with tirzepatide. He then offers insights into the new dyslipidemia guidelines, including addressing reproductive and hormone risk factors in cardiovascular risk assessment.
- In Memoriam: William W. Parmley, MD, MACCWilliam W. Parmley, MD, MACC, a transformative leader in cardiovascular medicine whose impact on the ACC spanned decades, passed away peacefully on May 23 at the age of 90, surrounded by his family.
- Ten Points to Remember From the Recent AHA Scientific Statement on "Cardiovascular Toxicity in Patients Treated for Childhood Cancer"Pediatric cardio-oncology has expanded in scope over the past several decades to address the ever-increasing issues related to cardiovascular disease (CVD) in patients with and survivors of cancer, related both to treatment modalities and the disease itself.
- ACCEL Lite: A Look At The ORBITA-CTO Trialn this interview, Allen J. Taylor, MD, FACC and John Davies, MBBS, PhD evaluate the ORBITA-CTO Trial.